Ivabradin Stada

Ivabradine, the active ingredient in Ivabradin Stada, is an If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina pectoris and for heart failure with reduced ejection fraction, helping to lower heart rate without affecting contractility in adult patients.

GNH USA supplies Ivabradin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured for the EU market and meets European quality standards and is distributed under strict regulatory oversight.

Ivabradin Stada (ivabradine) acts on the cardiac sinus node to reduce heart rate, and is used in the following cardiovascular conditions: - Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may lower hospitalization risk by decreasing heart rate. - Patients intolerant to beta‑blockers with chronic angina: provides heart‑rate control when beta‑blockers are unsuitable.

Ivabradin Stada may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Bradycardia: abnormally slow heart rate. - Phosphenes: transient luminous phenomena in the visual field. - Headache. - Dizziness. - Fatigue. - Visual blur.

Serious or Rare Side Effects: - Atrial fibrillation. - Severe bradycardia leading to syncope. - Significant hypotension. - Vision loss (rare). - Cardiac arrest (extremely rare).

When prescribing Ivabradin Stada, clinicians should consider several safety measures. - Baseline heart rate assessment: ensure resting heart rate is ≥ 50 bpm before initiation. - Contraindicated in acute decompensated heart failure. - Use caution in patients with hepatic impairment; dose adjustment may be required. - Monitor for symptomatic bradycardia during therapy. - Avoid concomitant strong CYP3A4 inhibitors without dose modification. - Store at room temperature: keep in the original container, protect from moisture and light.

Ivabradin Stada can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine exposure. - Concomitant bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Other If channel inhibitors (e.g., ranolazine): additive effect on heart‑rate lowering.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise plasma levels. - Drugs that prolong the QT interval: monitor ECG for arrhythmia risk. - Smoking: induces CYP3A4 and may reduce ivabradine efficacy.